Clinical Trial Update: Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating neoadjuvant erlotinib for operable NSCLC with EGFR mutations (Stage II/IIIA).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: NSCLC Stage II, NSCLC, Stage IIIA | Phase 2 | Status: UNKNOWN